Loading...
Loading...
- Nephros Inc NEPH has announced preliminary results and expects Q2 sales of approximately $2.2 million, representing a Y/Y increase of 40%
- "Revenue growth seems to be returning to pre-pandemic levels. In addition, revenue for the six months ended June 30, 2021, is expected to be over $5 million, a 20% increase over the same periods in 2020 and 2019, which we believe puts us in a strong position going into the second half of the year", said CEO Andy Astor.
- In addition, the Company submitted its Hemodiafiltration (HDF) System Assist Module for FDA 510(k) clearance.
- "Pending this FDA clearance, SRP is preparing for commercial launch at a limited number of dialysis clinics."
- Nephros ended the second quarter with approximately $8.3 million in cash on a consolidated basis.
- Nephros will formally announce its second-quarter results on August 5.
- Price Action: NEPH shares are down 0.95% at $9.55 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in